吸入可能な生物製剤の世界市場レポート 2025年

吸入可能な生物製剤の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR16.0％で59億米ドルに成長します。予測期間中の成長は、世界の高齢化人口の増加、新興市場におけるヘルスケアインフラの拡大、生物製剤治療に対する規制当局の支援の拡大、感染性呼吸器疾患の症例増加などに起因すると考えられます。この期間に予想される主な動向には、ドラッグデリバリーシステムの進歩、スマート吸入器技術の統合、エアロゾル科学の革新、生物学的製剤の発展、ナノ粒子ベースのキャリアの進歩などがあります。

呼吸器疾患の有病率の増加は、今後数年間の吸入可能な生物製剤市場の成長に大きく寄与すると予想されます。呼吸器疾患には、肺や、気道、鼻腔、肺を含む呼吸器系の他の構成要素に影響を及ぼす疾患や状態が含まれます。これらの疾患の増加は、喘息、慢性閉塞性肺疾患（COPD）、肺がんなどの疾患を悪化させ、有害な粒子状物質や汚染物質に個人をさらす大気汚染の増加に大きく起因しています。吸入可能な生物製剤は、ターゲットを絞った治療を肺に直接届けることで、全身的な副作用を抑えながら炎症を抑え、肺機能を改善するため、これらの症状に特に効果的です。例えば、2024年6月、オーストラリアの政府機関であるAustralian Institute of Health and Welfareは、2023年にはCOPDが全疾患負担の3.6％、呼吸器疾患負担の50％を占めると報告しました。その結果、呼吸器疾患の増加が吸入可能な生物製剤市場を大きく押し上げています。

吸入可能な生物製剤市場の主要企業は、患者のコンプライアンスを高め、より迅速な血糖コントロールを提供するために、吸入インスリンなどの画期的なソリューションの開発に注力しています。吸入インスリンとは、注射やインスリンポンプではなく、吸入によって肺から血流に直接送り込まれるインスリンのことです。この方法では、粉末またはエアロゾル化されたインスリンを吸入し、肺から吸収されて速やかに血流に入り、血糖値を調整します。例えば、2025年2月、インドの製薬会社シプラ・リミテッドは、1型および2型糖尿病の成人に注射針を使わない選択肢を提供する世界最速の吸入インスリンであるAfrezzaについて、中央医薬品標準管理機構から薬事承認を取得しました。この超速効型インスリンは、吸入後12～15分で効き始め、食事に対する自然なインスリン反応を忠実に模倣し、血糖コントロールを改善します。吸入インスリンは、特に注射に不安のある患者さんにとって、毎日の注射に代わるより快適な選択肢となり、インスリン治療のアドヒアランスを高めます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の吸入可能な生物製剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の吸入可能な生物製剤市場：成長率分析
• 世界の吸入可能な生物製剤市場の実績：規模と成長、2019年～2024年
• 世界の吸入可能な生物製剤市場の予測：規模と成長、2024年～2029年、2034年
• 世界の吸入可能な生物製剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の吸入可能な生物製剤市場：タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• ペプチドとタンパク質
• ワクチン
• モノクローナル抗体
• RNAiベースの治療法
• その他のタイプ
• 世界の吸入可能な生物製剤市場：剤形別、実績と予測、2019年～2024年、2024年～2029年、2034年
• ドライパウダー吸入器
• 定量噴霧式吸入器
• ネブライザー
• その他の剤形
• 世界の吸入可能な生物製剤市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の吸入可能な生物製剤市場：用途別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 呼吸器疾患
• 糖尿病
• がん
• その他の用途
• 世界の吸入可能な生物製剤市場、ペプチドとタンパク質の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• インスリン
• 成長ホルモン
• 酵素補充療法
• その他のペプチドとタンパク質
• 世界の吸入可能な生物製剤市場、ワクチンの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• インフルエンザワクチン
• その他の呼吸器ワクチン
• 世界の吸入可能な生物製剤市場、モノクローナル抗体の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 呼吸器モノクローナル抗体
• 免疫調節モノクローナル抗体
• その他のモノクローナル抗体
• 世界の吸入可能な生物製剤市場、RNAiベースの治療薬の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 呼吸器疾患に対するRNAベースの薬剤
• その他のRNAiベースの治療法
• 世界の吸入可能な生物製剤市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 遺伝子治療
• 低分子吸入薬
• その他の革新的な吸入可能な生物製剤

第7章 地域別・国別分析

• 世界の吸入可能な生物製剤市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界の吸入可能な生物製剤市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 吸入可能な生物製剤市場：競合情勢
• 吸入可能な生物製剤市場：企業プロファイル
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Medtronic PLC
• Moderna Inc.
• Pfizer Inc. and BioNTech SE
• Teva Pharmaceuticals
• Baxter International
• Lonza Group AG
• CanSino Biologics Inc.
• Cipla Ltd.
• Insmed Incorporated
• Kamada Pharmaceuticals
• Vectura Group plc
• F. Hoffmann-La Roche Ltd
• Iconovo AB
• Synairgen plc
• Ab Initio Pharma LLC

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 吸入可能な生物製剤市場2029年：新たな機会を提供する国
• 吸入可能な生物製剤市場2029年：新たな機会を提供するセグメント
• 吸入可能な生物製剤市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Inhalable biologics are biologic drugs that are delivered through the respiratory tract via inhalation. This method allows for targeted treatment of lung diseases or systemic therapy by directly reaching the lungs, which enhances the drug's effectiveness and minimizes side effects.

The primary types of inhalable biologics include peptides and proteins, vaccines, monoclonal antibodies, RNAi-based therapeutics, and others. Peptide and protein therapeutics are bioactive molecules designed to influence specific cellular pathways or replace deficient proteins. These biologics are available in various dosage forms, such as dry powder inhalers, metered-dose inhalers, nebulizers, and others, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. They are used in the treatment of respiratory diseases, diabetes, cancer, and other conditions.

The inhalable biologics market research report is one of a series of new reports from The Business Research Company that provides inhalable biologics market statistics, including inhalable biologics industry global market size, regional shares, competitors with an inhalable biologics market share, detailed inhalable biologics market segments, market trends and opportunities, and any further data you may need to thrive in the inhalable biologics industry. This inhalable biologic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The inhalable biologics market size has grown rapidly in recent years. It will grow from $2.79 billion in 2024 to $3.25 billion in 2025 at a compound annual growth rate (CAGR) of 16.4%. The growth during the historic period can be attributed to the rising prevalence of respiratory diseases globally, a growing demand for non-invasive delivery methods, increased awareness of the benefits of biologics, and the expanding research and investment in biopharmaceuticals.

The inhalable biologics market size is expected to see rapid growth in the next few years. It will grow to $5.90 billion in 2029 at a compound annual growth rate (CAGR) of 16.0%. The growth during the forecast period can be attributed to the increasing global aging population, the expansion of healthcare infrastructure in emerging markets, growing regulatory support for biologics therapy, and a rise in cases of infectious respiratory diseases. Key trends expected during this period include advancements in drug delivery systems, the integration of smart inhaler technology, innovations in aerosol science, developments in biologic drug formulations, and progress in nanoparticle-based carriers.

The growing prevalence of respiratory disorders is expected to significantly contribute to the growth of the inhalable biologics market in the coming years. Respiratory disorders encompass diseases and conditions affecting the lungs and other components of the respiratory system, including the airways, nasal passages, and lungs. The rise in these conditions is largely attributed to increasing air pollution, which exacerbates ailments such as asthma, chronic obstructive pulmonary disease (COPD), and lung cancer by exposing individuals to harmful particulate matter and pollutants. Inhalable biologics are particularly effective for these conditions as they deliver targeted treatments directly to the lungs, reducing inflammation and improving lung function with fewer systemic side effects. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that in 2023, COPD accounted for 3.6% of the total disease burden and 50% of the respiratory disease burden. Consequently, the rise in respiratory disorders is significantly boosting the inhalable biologics market.

Leading companies in the inhalable biologics market are focusing on developing groundbreaking solutions, such as inhaled insulin, to enhance patient compliance and provide faster glycemic control. Inhaled insulin is a form of insulin that is delivered directly into the bloodstream through the lungs via inhalation, rather than through injections or insulin pumps. This method involves inhaling a powder or aerosolized insulin, which is absorbed through the lungs and quickly enters the bloodstream to regulate blood sugar levels. For example, in February 2025, Cipla Limited, an India-based pharmaceutical company, received regulatory approval from the Central Drugs Standard Control Organization for Afrezza, the world's fastest inhaled insulin, offering a needle-free option for adults with type 1 and type 2 diabetes. This ultra-rapid-acting insulin works within 12 to 15 minutes of inhalation, closely mimicking the natural insulin response to meals and improving blood sugar control. Inhaled insulin presents a more comfortable alternative to daily injections, especially for patients with injection anxiety, enhancing adherence to insulin therapy.

In June 2022, Kindeva Drug Delivery Limited, a US-based pharmaceutical company, acquired iPharma Labs Inc. for an undisclosed amount. This acquisition allows Kindeva to integrate iPharma's expertise in inhalation formulations and early-stage drug development with its global capabilities in developing, commercializing, and manufacturing inhaled therapies. This combination strengthens Kindeva's position, enabling it to offer a more comprehensive, end-to-end solution for the development and manufacturing of respiratory medicines. iPharma Labs is a US-based contract research organization specializing in developing and formulating inhaled therapies, including inhalable biologics.

Major players in the inhalable biologics market are Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Medtronic PLC, Moderna Inc., Pfizer Inc. and BioNTech SE, Teva Pharmaceuticals, Baxter International, Lonza Group AG, CanSino Biologics Inc., Cipla Ltd., Insmed Incorporated, Kamada Pharmaceuticals, Vectura Group plc, F. Hoffmann-La Roche Ltd, Iconovo AB, Synairgen plc, Ab Initio Pharma LLC, Nanopharm Ltd, Ocugen Inc., MannKind Corporation.

North America was the largest region in the inhalable biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inhalable biologics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the inhalable biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The inhalable biologics market consists of sales of inhaled antibodies, inhalable mRNA-based therapeutics, inhaled vaccines, inhaled enzyme replacement therapies, and inhalable gene therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Inhalable Biologics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on inhalable biologics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for inhalable biologics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The inhalable biologics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Peptides And Proteins; Vaccines; Monoclonal Antibodies; RNAi-Based Therapeutics; Other Types
• 2) By Dosage Form: Dry Powder Inhalers; Metered Dose Inhalers; Nebulizers; Other Dosage Forms
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By Application: Respiratory Diseases; Diabetes; Cancer; Other Applications
• Subsegments:
• 1) By Peptides And Proteins: Insulin; Growth Hormones; Enzyme Replacement Therapies; Other Peptides And Proteins
• 2) By Vaccines: Influenza Vaccines; Other Respiratory Vaccines
• 3) By Monoclonal Antibodies: Respiratory Monoclonal Antibodies; Immunomodulatory Monoclonal Antibodies; Other Monoclonal Antibodies
• 4) By RNAi-Based Therapeutics: RNA-Based Drugs For Respiratory Diseases; Other RNAi-Based Therapeutics
• 5) By Other Types: Gene Therapies; Small Molecule Inhalable Drugs; Other Innovative Inhalable Biologics
• Companies Mentioned: Bayer AG; Sanofi SA; AstraZeneca plc; Novartis AG; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Inhalable Biologics Market Characteristics

3. Inhalable Biologics Market Trends And Strategies

4. Inhalable Biologics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Inhalable Biologics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Inhalable Biologics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Inhalable Biologics Market Growth Rate Analysis
• 5.4. Global Inhalable Biologics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Inhalable Biologics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Inhalable Biologics Total Addressable Market (TAM)

6. Inhalable Biologics Market Segmentation

• 6.1. Global Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Peptides And Proteins
• Vaccines
• Monoclonal Antibodies
• RNAi-Based Therapeutics
• Other Types
• 6.2. Global Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dry Powder Inhalers
• Metered Dose Inhalers
• Nebulizers
• Other Dosage Forms
• 6.3. Global Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Inhalable Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Respiratory Diseases
• Diabetes
• Cancer
• Other Applications
• 6.5. Global Inhalable Biologics Market, Sub-Segmentation Of Peptides And Proteins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insulin
• Growth Hormones
• Enzyme Replacement Therapies
• Other Peptides And Proteins
• 6.6. Global Inhalable Biologics Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Influenza Vaccines
• Other Respiratory Vaccines
• 6.7. Global Inhalable Biologics Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Respiratory Monoclonal Antibodies
• Immunomodulatory Monoclonal Antibodies
• Other Monoclonal Antibodies
• 6.8. Global Inhalable Biologics Market, Sub-Segmentation Of RNAi-Based Therapeutics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• RNA-Based Drugs For Respiratory Diseases
• Other RNAi-Based Therapeutics
• 6.9. Global Inhalable Biologics Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gene Therapies
• Small Molecule Inhalable Drugs
• Other Innovative Inhalable Biologics

7. Inhalable Biologics Market Regional And Country Analysis

• 7.1. Global Inhalable Biologics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Inhalable Biologics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Inhalable Biologics Market

• 8.1. Asia-Pacific Inhalable Biologics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Inhalable Biologics Market

• 9.1. China Inhalable Biologics Market Overview
• 9.2. China Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Inhalable Biologics Market

• 10.1. India Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Inhalable Biologics Market

• 11.1. Japan Inhalable Biologics Market Overview
• 11.2. Japan Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Inhalable Biologics Market

• 12.1. Australia Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Inhalable Biologics Market

• 13.1. Indonesia Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Inhalable Biologics Market

• 14.1. South Korea Inhalable Biologics Market Overview
• 14.2. South Korea Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Inhalable Biologics Market

• 15.1. Western Europe Inhalable Biologics Market Overview
• 15.2. Western Europe Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Inhalable Biologics Market

• 16.1. UK Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Inhalable Biologics Market

• 17.1. Germany Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Inhalable Biologics Market

• 18.1. France Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Inhalable Biologics Market

• 19.1. Italy Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Inhalable Biologics Market

• 20.1. Spain Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Inhalable Biologics Market

• 21.1. Eastern Europe Inhalable Biologics Market Overview
• 21.2. Eastern Europe Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Inhalable Biologics Market

• 22.1. Russia Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Inhalable Biologics Market

• 23.1. North America Inhalable Biologics Market Overview
• 23.2. North America Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Inhalable Biologics Market

• 24.1. USA Inhalable Biologics Market Overview
• 24.2. USA Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Inhalable Biologics Market

• 25.1. Canada Inhalable Biologics Market Overview
• 25.2. Canada Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Inhalable Biologics Market

• 26.1. South America Inhalable Biologics Market Overview
• 26.2. South America Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Inhalable Biologics Market

• 27.1. Brazil Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Inhalable Biologics Market

• 28.1. Middle East Inhalable Biologics Market Overview
• 28.2. Middle East Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Inhalable Biologics Market

• 29.1. Africa Inhalable Biologics Market Overview
• 29.2. Africa Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Inhalable Biologics Market Competitive Landscape And Company Profiles

• 30.1. Inhalable Biologics Market Competitive Landscape
• 30.2. Inhalable Biologics Market Company Profiles
  • 30.2.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Inhalable Biologics Market Other Major And Innovative Companies

• 31.1. Medtronic PLC
• 31.2. Moderna Inc.
• 31.3. Pfizer Inc. and BioNTech SE
• 31.4. Teva Pharmaceuticals
• 31.5. Baxter International
• 31.6. Lonza Group AG
• 31.7. CanSino Biologics Inc.
• 31.8. Cipla Ltd.
• 31.9. Insmed Incorporated
• 31.10. Kamada Pharmaceuticals
• 31.11. Vectura Group plc
• 31.12. F. Hoffmann-La Roche Ltd
• 31.13. Iconovo AB
• 31.14. Synairgen plc
• 31.15. Ab Initio Pharma LLC

32. Global Inhalable Biologics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Inhalable Biologics Market

34. Recent Developments In The Inhalable Biologics Market

35. Inhalable Biologics Market High Potential Countries, Segments and Strategies

• 35.1 Inhalable Biologics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Inhalable Biologics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Inhalable Biologics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer